


BIOMARK

Digital diagnostics – BioMark is a digital platform that connects patients, healthcare providers, laboratories and third-party administrators/payers - delivering automation and analytical insights to all stakeholders.



Patient platform:

- Visual display and trending of lab results
- Summary of health risks
- Supports 430+ biomarkers
- Supports multiple lab sources
- Blood sugar, medication, blood pressure, weight and HbA1c trackers
- Personalised recommendations



E-ordering:

- Reduce errors from manual data entry
- Key features: Search by package code or name, View package components, Auto-generation of specimen requirements, Printable request form with unique barcode and order history



Doctor clinic platform:

- View patient results in real time - accessible anywhere, anytime
- Visual display and trending of results
- Send notifications and reminders to patients



BioMark helps make sense of your medical data by helping you sort it, store it and understand it. In other words, BioMark makes your medical data more meaningful for you, so you can use it to prevent or manage disease. At the heart of BioMark's efforts to transform the value of medical data is an integrated and secure platform that organises, filters and extracts insights from medical data. Doctors base two-thirds of their clinical decisions on the biomarker data that is collected from the tissue and bodily fluids that are processed by medical laboratories. This is BioMark's starting point, BioMark focuses on medical data from these in vitro tests because while they are immensely important, they are also complex, often from multiple sources and difficult to track.

BioMark is leading PAH in our efforts to become a leading digital diagnostics and health data provider in the region

HEALTHCERT

Health records go digital to fight fakes, restart air travel in Singapore

In efforts to inspire confidence in cross-border travel amid the pandemic, Singapore is rolling out a tamper-proof digital system which captures an individual's COVID-19 test results. A portal is launched recently for authorized clinics to issue digital pre-departure COVID-19 test (PDT) certificates. The IQcert portal is compliant with GovTech's Healthcerts – an open source scheme and set of standards to ensure that the digital certificates can be widely recognized at local and overseas airports. Innovative Diagnostics and Quest Laboratories jointly developed the IQ portal together with the blockchain firm Trybe.ID which is based in Canada.



HEADQUARTER OFFICE
Frontech Centre
 15 Jalan Kilang Barat
 #06-01 to 06-04
 Singapore 159357
 T (65) 6235 6950
 F (65) 6733 8563

SATELLITE LABORATORIES
Paragon Medical
 290 Orchard Road
 #17-07/08/09
 Singapore 238859
 T (65) 6737 2788
 F (65) 6887 3249

HOSPITAL LABORATORIES
Farrer Park Hospital
 1 Farrer Park Station Road
 #02-01 Connexion
 Singapore 217562
 T (65) 6705 2822
 F (65) 6705 2941

MAIN LABORATORY
StarHub Green
 67 Ubi Avenue 1,
 North Wing
 #07-01 to 07/09/10,
 Singapore 408942
 T (65) 6275 5501
 F (65) 6277 0220

Royal Square at Novena
 1101 Irrawaddy Road
 #07-02
 Singapore 329565
 T (65) 6734 0778
 F (65) 6734 0773

Thomson Medical
 339 Thomson Road,
 Level 4
 Singapore 307677
 T (65) 6350 8804
 F (65) 6250 3032

Frontech Centre
 15 Jalan Kilang Barat
 #05-01 to 05-07 &
 #08-01 to 08-07
 Singapore 159357
 T (65) 6235 6950 / 6955
 F (65) 6733 8563

COLLECTION CENTRE
Camden Collection Centre
 1 Orchard Boulevard
 #09-06 to 09-07
 Singapore 248649
 T (65) 6333 6640
 F (65) 6333 6642



In pursuit of science, innovating for life

Congratulations to Innoquest Diagnostics on your successful merger!



Ginny Foo
CHIEF EXECUTIVE OFFICER



Dr. Tan Hong Wui
MEDICAL DIRECTOR



Dr. Anthony Stanislaus
CHIEF OPERATING OFFICER

Innovative Diagnostics (IDPL) and Quest Laboratories (Quest) are merging to become Innoquest Diagnostics Pte Ltd.

Through this pandemic, we learned that our national healthcare resources and medical preparedness is critical to react decisively and effectively to the next health emergency. The merger of IDPL and Quest will create the scale, resources and expertise Singapore needs to be ready for the next challenge.

IDPL and Quest have been serving our medical community for over 25 years. Innoquest sets out to be Singapore's preeminent medically managed innovator and healthcare leader; continuously striving to advance frontiers in medical science; building Singapore's laboratory of the future. The core laboratory is installed with the industry leading Roche total laboratory automation system with the capability to perform over 10,000 patient episodes a day. As a testimony to Innoquest's commitment to the highest clinical quality and patient care, Innoquest is one of a few labs in South East Asia with dual accreditation to College of American Pathologists (CAP) and ISO 15189. Innoquest will continually strive to empower the medical community with insightful and actionable information in their mission to transform healthcare delivery and improve patient outcomes.

Sponsoring companies:



ABOUT US

Quest Laboratories Pte Ltd (Quest) and Innovative Diagnostics Pte Ltd (IDPL) were established in 1995 and 1996 respectively. Together we are an amalgamation of seven laboratories which were acquired and merged in the last twenty years in Singapore. Pathology Asia Holdings (PAH) acquired both IDPL and Quest in September 2018. After a year of planning and restructuring, we began our journey to merge the two entities into one and formed Innoquest Diagnostics Pte Ltd. Innoquest is medically led by clinicians and supported by a deep bench of seasoned industry expertise. We believe that as clinicians we understand your needs and expectations. We remain steadfast to deliver in our vision and mission to build the lab of the future.

OUR VISION

To be the eminent innovator, and leader in advancing new frontiers in medical testing and diagnostics


OUR MISSION

To transform healthcare and improve the human condition


OUR VALUES

Our values shape our behaviour and guide our actions

- The pursuit of excellence
- Care for others
- Innovation that impacts
- Trust with integrity




GEOGRAPHIC COVERAGE OF PAH



BUSINESS HIGHLIGHT

- Financial Sponsors**
 - Pathology Asia Holdings (PAH) is led by our Group CEO, Dr. Christopher Ting and is backed by our financial sponsor, TPG Capital Asia
 - PAH owns the largest and fastest growing independent pathology businesses in Singapore and Malaysia, and aspires to be a South East Asian champion
 - There are currently over 2,000 staff under the PAH group of companies
- Operating Philosophy**
 - Comprehensive pure-play B2B pathology diagnostics business serving independent clinics, hospitals and corporates
 - Core operating philosophy of centralised laboratory testing, supported by decentralised pre- and post-analytics, coupled with high levels of automation and ICT integration
 - Unrelenting focus around medical leadership, delivering actionable insights, user experience and leading innovation



SISTER COMPANIES

GenomixLab

GenomixLab Malaysia

- A leading Genomics Laboratory in Malaysia
- 1st CAP accredited laboratory in Malaysia. CAP accreditation ensures quality results and standardised workflows.
- Speciality in NIPT, Oncology and Customised Panels
- State-of-the-art technology in genetic diagnostic testing
- Pharmacogenetic testing covering most therapeutic categories
- Winner of the CHT Award and GlobalHealth Asia Pacific Award
- First in Asia to conduct PGT-HLA Genotyping (Hi-Res) on Embryo Biopsies

Testing profile

- Reproductive genetics**
 - Prenatal using latest NGS technologies
 - Prenatal, Reproductive health and Paediatric
 - Sample tests: NiCE, PGT, PGT-A/M/SR, Mendelian disorder
- Oncology**
 - Solid tumour testing, liquid biopsy testing and hereditary cancer genetics testing
 - Sample tests: BRCA, Prostate, Lungs, etc.
- Others**
 - HLA Genotyping (high-resolution)
 - Pharmacogenetic testing
 - Cytogenetics and whole exome sequencing (WES)

Key management team



Dr Camille Cyncynatus
CEO, Genomics
• Ph.D. Biochemistry
• MBA INSEAD
• > 15 years in the diagnostics field working for multiple MNCs (Abbott, Natera and Pacific Biosciences)
• Spearheaded market entry of Panorama NIPT in SEA. #1 player in 2 years



Dr Keith Byron
COO, Genomics
• > 30 years experience managing specialised pathology services
• Previously the Scientific Director of Molecular Diagnostics at Gribbles, Healthscope & ACL
• Established Molecular Pathology services at the Royal Melbourne Hospital
• NATA/RCPA accreditation assessor



Dr John Yu
CSO, Genomics
• Ph.D. Biochemistry
• 7 years as a Developmental Biologist of Genetic Diseases (including at Oxford University)
• 9 years working experience with multiple MNCs (Siemens, Roche, Perkin Elmer)

GenomixLAB

4,000
Annual samples

230
Clients

>120
Panels

1st CAP
accredited
laboratory in
Malaysia

CAP
ACCREDITED
COLLEGE OF AMERICAN PATHOLOGISTS

Expansion of PAH's offerings into high value genomics (diagnostics and life sciences) via a leading genomics lab